Skip to main navigation Skip to search Skip to main content

Long-term follow-up after authorization of gene therapy: leveraging real-world data

  • Karin de Haart
  • , Keiko Asao
  • , Quazi Ataher
  • , Jamie Geier
  • , Jodie Hillen
  • , Kui Huang
  • , Peter G.M. Mol
  • , Donna Rivera
  • , Huifen Wang
  • , Hong Yang
  • , Siyan Zhan
  • , Wilhelmina E. Hoogendoorn
  • , Lourens T. Bloem

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)
14204 Downloads (Pure)

Abstract

Gene therapies are innovative treatments that could revolutionize healthcare. Given their unique mechanisms of action, methods of manufacturing and administration, and the potential for long-lasting impact, gene therapies require long-term follow-up (LTFU) of safety and effectiveness post-authorization, often using real-world data (RWD). With over 2000 gene therapies in development, there is a need for knowledge-building regarding LTFU studies. Here, we review regulatory, scientific, and operational requirements and considerations for LTFU studies using RWD from a global perspective. The insights in this review support post-authorization LTFU studies for gene therapies, thereby contributing to their safe and effective use.

Original languageEnglish
Article number104337
Number of pages11
JournalDrug Discovery Today
Volume30
Issue number5
DOIs
Publication statusPublished - May 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 9 - Industry, Innovation, and Infrastructure
    SDG 9 Industry, Innovation, and Infrastructure

Keywords

  • effectiveness
  • efficacy
  • gene therapy
  • long-term follow-up
  • pharmacoepidemiology
  • real-world data
  • safety

Cite this